カイダ　ケンイチ   KAIDA Kenichi   海田　賢一    所属   埼玉医科大学  医学部 総合医療センター　脳神経内科    職種   教授
論文種別	学術雑誌(原著)
言語種別	英語
査読の有無	査読あり
表題	Guillain-Barré syndrome: update on immunobiology and treatment.
掲載誌名	正式名：Expert review of neurotherapeutics
巻・号・頁	9(9),1307-19頁
著者・共著者	Kenichi Kaida,Susumu Kusunoki
発行年月	2009/09
概要	Growing experimental and clinical data have shed light on the pathophysiology of Guillain-Barré syndrome (GBS) and have further promoted the development of novel therapeutic strategies for the disorder. Elevated titer of antiganglioside antibodies is a characteristic of GBS. This may determine the clinical features of each case by binding to the sites where a target ganglioside antigen is localized. In experimental models of GBS and its variants, complementary inhibitory agents may exert neuroprotective efficacy by inhibiting antiganglioside antibody-mediated activation of the classical pathway. Complement-mediated disruption of the voltage-gated sodium channel cluster has been shown to be a principal cause of conduction failure in the model of acute motor axonal variants of GBS, protected by a complement inhibitor. Anti-GQ1b antibody-mediated injury at motor nerve terminals is also protected by complement inhibitors. In the future many kinds of drug candidates that inhibit activation of the complement system at various stages will be used in models of autoimmune neuropathy, in future applied to clinical trials for GBS and its variants. Complement-independent blockade of voltage-g
DOI	10.1586/ern.09.77
PMID	19769446